In a bid to attract new entrants to the market, financial services firm SoFi is offering a significant stock bonus of up to $1,000 for opening a self-directed investment account, eliminating traditional barriers like commissions and minimums.
USA Rare Earth Inc. (NASDAQ: USAR) sees its price target significantly raised by Canaccord Genuity and Benchmark following a landmark $1.6 billion commitment from the U.S. CHIPS Program, accelerating its plans to build a domestic rare earth supply chain.
As the Bank of England prepares for a leadership transition in 2028, a debate ignited by former Fed governor Kevin Warsh gains traction: should central banks shed ancillary roles and return to their core mission of price stability?
New data reveals tariffs imposed on key materials like steel and aluminum pushed nonresidential construction costs up 3.2% in 2025, with economists warning of continued pressure and broader impacts on equipment prices in the year ahead.
Analyst firm Clear Street has raised its price target for Critical Metals Corp. (CRML) to $20, citing a strategic joint venture with a Saudi industrial group to build a rare earth processing facility. The move aims to diversify supply chains away from China and support Western defense needs.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
Analysts remain divided on Gogo Inc.'s trajectory as the in-flight connectivity provider navigates its 5G network launch against a backdrop of strategic shifts and evolving satellite technology debates.
Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.
Investment firm Maxim Group reaffirms its Buy rating and $1.50 price target for Strive Inc., following the company's transformative acquisition of Semler Scientific, which positions it as a major corporate Bitcoin holder and expands its healthcare tech footprint.
Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.
Michigan's Attorney General has formally demanded the return of state funds from Gotion Inc., a Chinese battery manufacturer, following the collapse of its planned $2.4 billion facility. The move highlights growing tensions over foreign investment in U.S. strategic industries.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
While Roth accounts dominate the retirement planning conversation, a closer look at current tax laws and long-term income strategies reveals a compelling case for prioritizing pre-tax contributions. We examine the data with an expert and explore what gold's historical returns tell us about diversification.
WisdomTree reports record assets under management of $144.5 billion for 2025, driven by $8.5 billion in net inflows and strategic acquisitions. The firm forecasts continued margin expansion and highlights digital assets, European thematics, and private markets as key growth engines for the coming year.
As SpaceX reportedly engages banks for a potential 2026 public offering, the pre-IPO secondary market for late-stage tech giants is booming, offering a critical liquidity valve and reshaping the path to going public.
Standex International reports consecutive quarters of record profitability, driven by strategic acquisitions and growth in electrical grid and aerospace markets, while navigating global trade uncertainties.
Cocoa prices staged a modest technical rebound on Friday, halting a month-long slide that had pushed contracts to their lowest levels in over two years. The move higher, driven by short-covering in an oversold market, comes amid a complex backdrop of abundant near-term supplies, weakening demand, and a tightening longer-term outlook.
Shares of Cushman & Wakefield have surged 35.8% in six months, dramatically outpacing the broader market. While strong quarterly results fueled the climb, a deeper look at the firm's long-term financial health reveals potential headwinds that could give investors pause.
